全球治疗性血浆交换市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

预计到 2032 年，全球治疗性血浆交换市场的市场规模将从 2023 年的 25.3 亿美元达到近 51.7 亿美元，2024-2032 年研究期间的CAGR为 8.26%。

治疗性血浆置换 (TPE)，也称为血浆置换术，是一种去除、处理、返回患者血浆的医疗程序。 TPE 的主要目标是透过选择性去除血浆成分（例如抗体、免疫复合物和其他可能导致各种医疗状况的物质）来改变患者血液的成分。该过程涉及一种称为离心机的设备，该设备将血液分离成各种成分，从而有针对性地去除血浆。

市场动态

治疗性血浆置换市场是由自体免疫疾病、神经系统疾病和神经肌肉疾病的日益普及所推动的。医疗技术的进步推动了这一成长，带来了更有效率的 TPE 设备并改善了患者的治疗效果。肾臟病治疗肾臟疾病的应用不断扩大，加上医疗保健专业人员和患者意识的不断提高，都有助于市场的扩张。全球人口老化，对自体免疫疾病和神经系统疾病的易感性更高，刺激了对 TPE 干预措施的需求。医疗保健支出的增加、政府倡议以及医疗机构和研究组织之间的合作支持了 TPE 的可近性。临床研究和治疗指南以及患者对非侵入性治疗的偏好在塑造市场方面发挥关键作用。此外，传染病的全球影响强调了对多种治疗方案的需求，进一步促进了治疗性血浆交换市场的动态成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球治疗性血浆置换市场的各个细分市场进行了包容性评估。治疗性血浆交换行业的成长和趋势为这项研究提供了整体方法。

市场区隔

治疗性血浆交换市场报告的这一部分提供了国家和地区层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人群以及即将到来的机会。

按疾病适应症

• 神经系统疾病（慢性资讯性多髓鞘性多发性神经病变、重症肌无力、多发性坏死、视神经脊髓炎、格林-巴利综合症）
• 肾臟疾病（肾臟移植后排斥、抗肾丝球基底膜 (Gsm) 疾病、韦格纳肉芽肿病）
• 血液学疾病（血栓性血小板减少性紫斑症、溶血性尿毒症症候群、冷胆菌素血症、多发性骨髓瘤、代谢障碍、纯合子女性高胆固醇血症、爆发性 Wiburn 病）
• 其他的

按最终用户

• 医院
• 专业中医
• 门诊手术中心

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的治疗性血浆交换市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。治疗性血浆交换市场的主要参与者包括旭化成公司、​​百特国际公司、泰尔茂公司、B. Braun SE、Fresenius Kabi AG、SB-Kawasumi Laboratories Inc.、Haemonetics Corporation、Cerus Corporation、Charles River Laboratories 、Medica SpA。该部分包含竞争格局的整体视图，其中包括各种策略发展，例如关键併购、未来能力、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：治疗性血浆交换 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 依疾病适应症进行的市场吸引力分析
  • 最终用户的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球治疗性血浆交易市场分析：按疾病适应症

• 按疾病适应症概述
• 历史和预测数据
• 按疾病指征分析
• 神经系统疾病（慢性资讯性多髓鞘性多发性神经病变、重症肌无力、多发性坏死、视神经脊髓炎、格林-巴利综合症）
• 肾臟疾病（肾臟移植后排斥、抗肾丝球基底膜 (GSM) 疾病、韦格纳肉芽肿病）
• 血液学疾病（血栓性血小板减少性紫斑症、溶血性尿毒症症候群、冷胆菌素血症、多发性骨髓瘤、代谢障碍、纯合子女性高胆固醇血症、爆发性 Wiburn 疾病）
• 其他的

第 6 章：全球治疗性血浆交易市场分析：依最终用户分类

• 最终用户概述
• 历史和预测数据
• 最终用户分析
• 医院
• 专业中医
• 门诊手术中心

第 7 章：全球治疗性血浆交易市场分析：依地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 8 章：治疗性血浆交换公司的竞争格局

• 治疗性血浆交换市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 9 章：公司简介

• 顶级公司市占率分析
• 市场集中度
• Asahi Kasei Corporation
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Baxter International Inc
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Terumo Corporation
• 公司简介
• 公司收入
• 产品
• 最近的发展
• B. Braun SE
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Fresenius Kabi AG
• 公司简介
• 公司收入
• 产品
• 最近的发展
• SB-Kawasumi Laboratories Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Haemonetics Corporation
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Cerus Corporation
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Charles River Laboratories
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Medica SpA
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

The global demand for Therapeutic Plasma Exchange Market is presumed to reach the market size of nearly USD 5.17 BN by 2032 from USD 2.53 BN in 2023 with a CAGR of 8.26% under the study period 2024 - 2032.

Therapeutic plasma exchange (TPE), also known as plasmapheresis, is a medical procedure that removes, treats, retreturnsatient's blood plasma. The primary objective of TPE is to modify the composition of the patient's blood by selectively removing plasma components, such as antibodies, immune complexes, and other substances that may contribute to various medical conditions. The procedure involves a device known as a centrifuge, which separates blood into its components, allowing the targeted removal of plasma.

MARKET DYNAMICS

The Therapeutic plasma exchange market is driven by the increasing prevalence of autoimmune disorders, neurological diseases, and neuromuscular conditions. The growth is propelled by advancements in medical technology, leading to more efficient TPE equipment and improved patient outcomes. Expanding applications in nephrology for treating kidney disorders, coupled with rising awareness among healthcare professionals and patients, contribute to the market's expansion. The aging global population, with a higher susceptibility to autoimmune and neurological disorders, fuels the demand for TPE interventions. Increased healthcare expenditure, government initiatives, and collaborations between healthcare institutions and research organizations support the accessibility of TPE. Clinical research and treatment guidelines play a pivotal role in shaping the market, along with patient preferences for non-invasive treatments. Additionally, the global impact of infectious diseases emphasizes the need for versatile treatment options, further contributing to the dynamic growth of the Therapeutic plasma exchange market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of therapeutic plasma exchange. The growth and trends of therapeutic plasma exchange industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the therapeutic plasma exchange market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Indication

• Neurological Disorders (Chronic Infiommatory Domyelinating Polyneuropathy, Myasthenia Grav, Multiple Secrosis, Neuromyelitis Optica, Guillain-Barre Syndrome)
• Renal Disorders (Post-Renal Transplant Rejection, Anti-Glomerular Basement Membrane (Gsm) Disease, Wegener'S Granulomatosis)
• Hematology Disorders (Thrombotic Thrombocytopenic Purpura, Hemalytic Uremic Syndrome, Cryngichulinemia, Multiple Myeloma, Metabolic Disorders, Homozygous Femilial Hypercholesterolemie, Fulminent Wiburn'S Disease)
• Others

By End-User

• Hospitals
• Specialty Chnics
• Ambulatory Surgice Centers

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Therapeutic Plasma Exchange market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Therapeutic Plasma Exchange market include Asahi Kasei Corporation, Baxter International Inc, Terumo Corporation, B. Braun SE, Fresenius Kabi AG, SB-Kawasumi Laboratories Inc., Haemonetics Corporation, Cerus Corporation, Charles River Laboratories, Medica S.p.A. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . THERAPEUTIC PLASMA EXCHANGE - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Disease Indication
  • 3.7.2 Market Attractiveness Analysis By End-user
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET ANALYSIS BY DISEASE INDICATION

• 5.1 Overview by Disease Indication
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Disease Indication
• 5.4 Neurological Disorders (Chronic infiommatory Domyelinating Polyneuropathy, Myasthenia Grav, Multiple Secrosis, Neuromyelitis Optica, Guillain-Barre Syndrome) Historic and Forecast Sales by Regions
• 5.5 Renal Disorders (Post-renal Transplant Rejection, Anti-glomerular Basement Membrane (GSM) Disease, Wegener's Granulomatosis) Historic and Forecast Sales by Regions
• 5.6 Hematology Disorders (Thrombotic Thrombocytopenic Purpura, Hemalytic Uremic Syndrome, Cryngichulinemia, Multiple Myeloma, Metabolic Disorders, Homozygous Femilial Hypercholesterolemie, Fulminent Wiburn's Disease) Historic and Forecast Sales by Regions
• 5.7 Others Historic and Forecast Sales by Regions

6 . GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET ANALYSIS BY END-USER

• 6.1 Overview by End-user
• 6.2 Historical and Forecast Data
• 6.3 Analysis by End-user
• 6.4 Hospitals Historic and Forecast Sales by Regions
• 6.5 Specialty Chnics Historic and Forecast Sales by Regions
• 6.6 Ambulatory Surgice Centers Historic and Forecast Sales by Regions

7 . GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE THERAPEUTIC PLASMA EXCHANGE COMPANIES

• 8.1. Therapeutic Plasma Exchange Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF THERAPEUTIC PLASMA EXCHANGE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Asahi Kasei Corporation
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Baxter International Inc
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Terumo Corporation
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. B. Braun SE
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Fresenius Kabi AG
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. SB-Kawasumi Laboratories Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Haemonetics Corporation
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Cerus Corporation
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. Charles River Laboratories
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments
• 9.12. Medica S.p.A
  • 9.12.1. Company Overview
  • 9.12.2. Company Revenue
  • 9.12.3. Products
  • 9.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Disease Indication (USD MN)
• Neurological Disorders (Chronic infiommatory Domyelinating Polyneuropathy, Myasthenia Grav, Multiple Secrosis, Neuromyelitis Optica, Guillain-Barre Syndrome) Market Sales by Geography (USD MN)
• Renal Disorders (Post-renal Transplant Rejection, Anti-glomerular Basement Membrane (GSM) Disease, Wegener's Granulomatosis) Market Sales by Geography (USD MN)
• Hematology Disorders (Thrombotic Thrombocytopenic Purpura, Hemalytic Uremic Syndrome, Cryngichulinemia, Multiple Myeloma, Metabolic Disorders, Homozygous Femilial Hypercholesterolemie, Fulminent Wiburn's Disease) Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by End-user (USD MN)
• Hospitals Market Sales by Geography (USD MN)
• Specialty Chnics Market Sales by Geography (USD MN)
• Ambulatory Surgice Centers Market Sales by Geography (USD MN)
• Global Therapeutic Plasma Exchange Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Therapeutic Plasma Exchange Report
• Market Research Process
• Market Research Methodology
• Global Therapeutic Plasma Exchange Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Disease Indication
• Market Attractiveness Analysis by End-user
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Disease Indication (USD MN)
• Neurological Disorders (Chronic infiommatory Domyelinating Polyneuropathy, Myasthenia Grav, Multiple Secrosis, Neuromyelitis Optica, Guillain-Barre Syndrome) Market Sales by Geography (USD MN)
• Renal Disorders (Post-renal Transplant Rejection, Anti-glomerular Basement Membrane (GSM) Disease, Wegener's Granulomatosis) Market Sales by Geography (USD MN)
• Hematology Disorders (Thrombotic Thrombocytopenic Purpura, Hemalytic Uremic Syndrome, Cryngichulinemia, Multiple Myeloma, Metabolic Disorders, Homozygous Femilial Hypercholesterolemie, Fulminent Wiburn's Disease) Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by End-user (USD MN)
• Hospitals Market Sales by Geography (USD MN)
• Specialty Chnics Market Sales by Geography (USD MN)
• Ambulatory Surgice Centers Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.